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Hepatitis B (HBV) remains a global health problem despite the 
availability of effective vaccines since 1982 and effective antiviral 
therapy. Two billion people have serologic evidence of past or 
ongoing HBV infection and an estimated 257 million people or 
3.5% of the world’s population, are chronically infected with HBV.[1] 
The lifetime risk of cirrhosis, liver failure and hepatocellular 
carcinoma (HCC) is 15 - 40%. Globally, hepatitis B mortality is 
increasing, while HIV/AIDS mortality is decreasing with the advent 
of antiretroviral therapy (ART).[2] Globally in 2015, HBV caused 
887 220 deaths: acute hepatitis (n=87 076), cirrhosis (n=462 690) 
and HCC (n=337 454); in Africa, HBV was responsible for 87 890 
deaths.[1]
In May 2016, the World Health Organization (WHO) adopted a 
global hepatitis strategy with the goal of eliminating viral hepatitis 
as a public health threat by 2030. The targets to be achieved by 2030 
are ambitious: 90% reduction in new cases of chronic hepatitis B 
and C; 65% reduction in mortality due to hepatitis B and C; and 
80% of treatment-eligible persons with chronic hepatitis B and C 
infections being treated.[3] 
Hepatitis B epidemiology
HBsAg seroprevalence varies geographically. According to the 
recent 2017 WHO Global Hepatitis Report, the number of HBsAg-
positive individuals was highest in the Western Pacific (115 million, 
prevalence estimate 6.2%; 95% uncertainty interval 5.1 - 7.6%) 
and Africa (60 million, prevalence estimate 6.1%; 95% uncertainty 
interval 4.6 - 8.5%) regions, which together accounted for 68% 
of the global burden.[1] The annual incidence of hepatocellular 
carcinoma correlates with the hepatitis B surface antigen (HBsAg) 
seroprevalence; the highest incidence is found in sub-Saharan Africa 
(SSA) and South East Asia.
In the absence of effective mother-to-child-transmission (MTCT) 
prophylaxis, HBV endemicity and chronicity is established in early 
childhood, with HBsAg seroprevalence studies showing no difference 
between children aged 5 - 9 years and adults.[4] The risk of chronicity 
of HBV is determined by the age of acquisition of infection: 90% after 
neonatal infection (in children born to HBeAg-positive or highly 
viraemic mothers), 20 - 50% with childhood infection (<5 years of 
age) and <5% for adults >20 years.
HIV/HBV co-infection has a further impact as HIV promotes 
a more aggressive natural history of hepatitis B. HIV co-infection 
promotes increased HBV replication and rates of HBV reactivation; 
increased  hepatitis B e-antigen (HBeAg) seroconversion; increased 
rates of occult HBV; chronicity of newly acquired HBV infections 
with a five times faster progression to fibrosis and cirrhosis; HCC also 
occurs at a younger age and is more aggressive.[5-16] 
Achieving elimination of hepatitis B
In order to achieve the WHO’s ambitious 2030 targets of elimination, 
it will be essential to recognise the burden of disease within one’s own 
country, i.e. know the seroprevalence and potential high-risk groups; 
implement HBV vaccine programmes for high-risk groups; address 
the risk of MTCT; identify HBV-infected individuals and ensure 
linkage to care; recognise and address potential stigma associated 
with hepatitis B; and have implementable preventive, surveillance 
and treatment strategies. It is imperative to recognise and address 
potential challenges associated with achieving the elimination of HBV 
while recognising that hepatitis B and its associated complications are 
entirely vaccine preventable.
Universal HBV vaccination
Vaccination remains the cornerstone of any elimination strategy. 
The WHO recommended incorporation of HBV vaccination into 
the Expanded Program of Immunization (EPI) in 1991 as the most 
effective way to reduce the global burden of HBV. WHO’s 2030 target 
is 90% full HBV vaccine coverage and in 2015, the global HBV 3 dose 
vaccine coverage was 84%, but only 77% in the WHO Africa region. 
In contrast, the Western Pacific region has achieved 90% coverage.[1,17]
Universal vaccination has globally decreased HBsAg prevalence 
in children under 5 years of age from 4.7% in pre-vaccination era 
to 1.3% in 2015, but the prevalence in the WHO Africa region 
remains high at 3%.[1] The Western Pacific region has reduced their 
HBsAg prevalence in under-5-year-olds to 0.9%. By 2013, universal 
HBV vaccination had prevented 14.2 million cases of chronic HBV 
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infection among children aged 0 - 5 years worldwide and more than 
1.3 million deaths.[18] 
Mother-to-child transmission of hepatitis B
HBV MTCT prevention strategies include antenatal HBsAg screening, 
hepatitis B birth-dose (HepB-BD) vaccination, administration of 
hepatitis B immunoglobulin to the newborn, and third-trimester 
antiviral therapy for women with high infectivity risk (HBeAg-
positive and/or HBV DNA >200 000 IU/mL) and full HBV vaccine 
coverage.[19-21] Modelling studies have suggested that an 80% global 
scale-up of HepB-BD vaccination plus infant vaccination, compared 
with scaling-up of infant vaccination alone, could avert 18.7 million 
new chronic infections over the next 15 years, confirming its 
importance as a PMTCT tool.[22]
In 2009, WHO recommended HepB-BD vaccination, with a 
monovalent HBV vaccine administered within 24 hours of delivery 
for all countries.[23] However, globally in 2014, only 96 of 194 
countries (49%) reported offering HepB-BD as part of their national 
immunisation programmes and <38% of babies born worldwide 
received HepB-BD within 24 hours after birth.[1,17] Of concern, 
only 11 of 47 WHO Africa region countries (23%) had introduced 
HepB-BD vaccine by July 2017, and this is far below the WHO 2030 
vaccination target of 90% birth-dose vaccination coverage.[24] HepB-
BD vaccine given within 24 hours after birth and followed by at least 
two subsequent doses, is ~90% effective at preventing perinatal HBV 
infection. Innovative approaches to ensure timeous administration of 
Hep B-BD vaccine that have been successfully employed in Vietnam, 
Indonesia and China, i.e pregnancy tracking and administration of 
the Hep B-BD by village lay workers as well as the use of compact 
pre-filled auto-disposable devices (Uniject; Becton, Dickinson and 
Company, USA ) are translatable to SSA.[25-27]
While the risk of MTCT of HIV is well recognised and policies 
are in place to screen all pregnant women for HIV and initiate ART, 
many countries in SSA do not have similar policies in place for 
HBV despite WHO recommending antenatal HBsAg screening in 
countries where HBsAg prevalence is ≥2%.[1,28,29] This is concerning 
as the annual number of infants perinatally infected with HBV is 
twice the number of incident paediatric HIV infections in SSA.[30] 
Standard-of-care procedures need to be in place to communicate 
the HBsAg status to the delivery unit to assess the need for third-
trimester tenofovir prophylaxis for HBeAg-positive or highly 
viraemic (HBV DNA >200 000 IU/ml) pregnant women and to 
emphasise the importance of timely HBV birth-dose vaccination 
within 24 hours of delivery.[28] Timeous administration is important 
as there is an increased risk of HBV transmission if HB-BD is given 
7 days after delivery compared to 1 - 3 days post delivery (OR 8.6).[28] 
Immunisation programmes also need to ensure a timely second dose 
of HBV vaccination to infants born to mothers with chronic HBV 
infection as the risk of becoming chronically infected was 3.74 times 
(95% confidence interval (CI) 0.97 - 14.39) higher if the interval 
between the first and the second doses exceeded 10 weeks.[31] 
Identification of HBsAg-positive pregnant women also provides the 
opportunity to identify potentially HBV-infected partners, siblings 
and children and thereby link them to care and break ongoing 
cycles of infection.
Efficacy of universal hepatitis B vaccination: Impact on 
liver disease
This has proved exemplary in Taiwan, where universal vaccination, 
introduced in 1984, together with a catch-up vaccination programme 
and improved maternal screening, resulted in a decrease in the 
prevalence of HBsAg positivity in children aged <15 years from 9.8% 
in 1984 to 0.3% in 2009 and continues to decrease 30 years after 
initiation of universal vaccination.[32-34] Furthermore, HCC incidence 
per 105 person-years has decreased from 0.92 in unvaccinated to 0.23 
in vaccinated cohorts.[35]
In Alaska, universal newborn HBV vaccination, vaccine catch-
up programmess and mass screening since 1981 have eliminated 
acute symptomatic HBV infection and early-onset HCC as a public 
health threat among Alaskan Native (AN) children. The incidence of 
acute symptomatic HBV infection in AN persons <20 years of age 
decreased from 19/100 000 in 1981 - 1982 to no reported cases since 
1992. The incidence of HCC in AN persons <20 years decreased from 
3/100 000 in 1984 – 1988, with no reported cases since 1998. The 
number of identified HBsAg-positive AN persons <20 years declined 
from 657 in 1987 to 2 cases identified since 1999; the last HBsAg-
positive AN person <20 years of age was identified in 2010.[36]
A similar decline in HBsAg seroprevalence rate and in HCC 
incidence has been seen in other hepatitis B endemic countries which 
have implemented universal HBV vaccination.[37-39]
Full HBV vaccine coverage is important, as incomplete 
immunisation has been shown to be an important risk predictor for 
HCC (HR 2.52; 95% confidence interval (CI) 1.25 - 5.05; p=0.0094) 
and chronic liver disease (HR 6.27; 95% CI 3.62 - 10.84; p<0.0001) 
after correction for maternal HBsAg status.[40]
Public-private partnerships play an important role in achieving 
the elimination of hepatitis B. The success of HepB-BD vaccine 
and full vaccine coverage in preventing childhood HBV acquisition 
has been demonstrated in China. A partnership between Gavi, 
the Vaccine Alliance and the Chinese government supporting 
free HepB-BD vaccination in combination with up-scaling of the 
full HBV vaccine schedule and utilising village lay healthcare 
workers to administer the HepB-BD vaccine, has reduced HBsAg 
seroprevalence in 2009 to 0.96% in children <5 years of age 
compared with 9.67% in 1992.[41] 
Durability of universal HBV vaccination 
In a 30-year follow-up study, 243 individuals of a cohort of 
1 578 AN adults and children who had responded to the original 
primary series but received no subsequent booster doses were 
screened for immunity; 125 (51%) individuals had an anti-HBs 
level ≥10 mIU/mL at 30 years. Among participants with anti-
HBs levels <10 mIU/mL who were available for follow-up, 88% 
(n=75/85) responded to a booster dose with an anti-HBs level ≥10 
mIU/mL at 30 days, indicating immunological memory. Thus, 
~90% (range 74 -100%) had evidence of protection 30 years after 
vaccination.[42]
A meta-analysis of 22 studies assessed 11 090 persons 5 - 20 years 
post vaccination and showed no evidence of chronic infection and 
0.7% evidence of past exposure (anti-HBc-positive).[43] Boosters were 
not needed in immunologically competent individuals following a 
full primary course of HBV vaccination.[43,44]
Identification of HBV-infected 
individuals and linkage to care
In 2015, it was estimated that globally only 9% of HBV-infected 
individuals (22 million) were aware of their diagnosis and only 8% of 
diagnosed HBV-infected individuals (1.7 million) had been treated.[1] 
In order to prevent the life-threatening complications of cirrhosis, 
liver failure and HCC, it is essential to identify HBV-infected 
individuals to assess the need for treatment and appropriate 
frequency of follow-up. Accurate WHO pre-qualified HBV point-
of-care (POC) testing that can be easily administered at primary 
levels of healthcare is essential to upscale diagnosis and treatment. 
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The PROLIFICA project has validated 3 point-of-care rapid 
diagnostic tests (Determine, Vikia and Espline), both in the field and 
laboratory settings in the Gambia. All 3 tests had acceptable ranges 
of diagnostic accuracy and are inexpensive alternatives to laboratory-
based testing.[45] Once diagnosed, HBV-infected individuals need 
to be linked to care and this will require the establishment of clear 
pathways of referral. Less than 20% HBV-infected individuals require 
treatment and the need for treatment and frequency of follow-up is 
determined by age, ALT, presence of fibrosis, HBeAg status, HBV 
DNA levels and family history of cirrhosis or HCC.[46]
The PROLIFICA project also demonstrated that large scale test-
and-treat programmes are feasible and cost-effective in endemic 
countries such as SSA.[47,48]
Appropriate HBV antiviral therapy has been shown to have an 
impact on the development of cirrhosis and risk of HCC, improving 
liver-related and all-cause mortality.[49-52] Lamivudine, entecavir 
and tenofovir have all been shown to decrease mortality. Tenofovir, 
which has a high barrier against resistance, is the WHO preferred 
antiviral.[46] Unfortunately, although tenofovir and lamivudine/
emtricitabine are widely available as part of ART, these nucleotide 
analogues are not always accessible to patients with HBV mono-
infection in many SSA countries.
Addressing important co-factors in 
HCC development in chronic HBV 
infection
There are a number of important co-factors that increase the risk 
of hepatitis B-related HCC that also need to be addressed.[53,54] The 
mycotoxin aflatoxin B1 (AFB1) is potent hepatocarcinogen that 
contaminates crops, especially maize, groundnuts and sorghum 
in tropical and subtropical climates such as South-East Asia and 
sub-Saharan Africa, especially in West Africa. AFB1 contamination 
occurs during the growth of crops and during improper storage, 
and individuals are exposed as early as in utero as AFB1 crosses the 
placenta. Subsistence farming, poor crop storage and suboptimal 
processing increase the risk of AFB1 exposure.[55] HBV and AFB1 
are synergistically hepatocarcinogenic and a systematic review and 
meta-analysis revealed an overall population attributable risk of 
AFB1-related HCC of 17% (14 - 19%), with 21% in HBsAg-positive 
and 8.8% in HBsAg-negative individuals. The relative risk of HCC 
was 54.1 (95% CI 21.3 - 137.7) with dual exposure.[56]
Other important HCC co-factors that need to be addressed are 
alcohol, iron overload and increasingly obesity and associated non-
alcoholic fatty liver disease.[57,58]
Cumulative HCC risk scores for HBV-related HCC have mainly 
been validated in Asian patients and are weighted for the presence 
of cirrhosis and increasing age.[59] These HCC risk-predictor models 
have not been validated in SSA, where 40% of HCC occurs in young 
non-cirrhotic patients. 
Conclusion
Hepatitis B and its associated complications of cirrhosis, liver failure 
and HCC are entirely vaccine preventable. In order to achieve the 
WHO 2030 vision of eliminating HBV, it is imperative that countries 
implement the WHO recommendations of HBV birth-dose vaccine, 
full vaccine coverage, and upscale diagnosis and linkage to care of 
HBV-infected individuals. 
The WHO Global Health Sector Strategy on Viral Hepatitis is to 
reduce new cases of chronic HBV infection by 30% by 2020, which is 
equivalent to 1% HBsAg prevalence amongst children aged 5 years, 
aiming for 0.1% HBsAg prevalence in 5-year-olds by 2030.
The full clinical impact of HBV birth-dose vaccination will take 2 - 3 
decades and it is essential that HBV-infected individuals are linked 
to care with appropriate therapy and follow-up, and high-risk non-
immune individuals are vaccinated. Although antiviral therapy has 
reduced both liver-related and all-cause mortality, the risk of HCC 
in HBV-infected individuals, albeit reduced, is not eliminated and 
lifelong antiviral therapy and follow-up are usually necessary. Future 
therapeutic endeavours are aimed at not only a functional cure but 
also a virological cure with eradication of the intrahepatic HBV 
reservoir, the covalently closed circular HBV DNA.[60]
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